Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Divi's Laboratories Ltd.
NSE: DIVISLAB
|
BSE: 532488
|
ISIN: INE361B01024
|
Industry: Pharmaceuticals
|
Expensive Performer
6132.0000
-58.50
(
-0.94
%)
NSE
Aug 28, 2025
15:31 PM
Volume:
415.5K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Divi's Laboratories Ltd.
05 Nov 2019
6132.00
-0.94%
Divi's Labs (ADD): Good Q2 beat; FY20 margin guidance cut is negative
Buy:
Divi's Laboratories Ltd.
by
BOB Capital Markets Ltd.
Target: 1765
Recommendation
Target
BOB Capital Markets Ltd.
Overall Revenue/EBITDA were 13% ahead of our estimates but largely in-line with consensus.
Divi's Laboratories Ltd. is trading
below its 30 day SMA
of 6355.8
More from Divi's Laboratories Ltd.
Recommended
Chart of the Week: Domestic demand gives finance, hotels, jewellery and IT services a boost
The Baseline |
28 Aug 2025, 04:35PM
Market closes lower, Tata Steel invests Rs 3,104 crore in its subsidiary T Steel Holdings
Trendlyne Marketwatch |
28 Aug 2025, 03:59PM
Custom synthesis business drives growth for Divi’s Laboratories
|
10 Mar 2022